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THE DEVELOPMENT OF OSTEOPOROSIS AFTER BARIATRIC SURGERY: 
A REVIEW 
PORSHA L. LARK 
ABSTRACT 
Background 
Bariatric surgery is an effective weight loss treatment modality for people with morbid 
obesity, however, there may be a negative impact on postoperative bone health. This 
review summarizes changes of different bone mineral density dual-energy x-ray 
absorptiometry measurements, with specific attention to the laparoscopic sleeve 
gastrectomy and the roux-en-y gastric bypass. 
 
Methods 
PubMed and the Cochrane Library searches yielded 156 articles published before 
November 2017. The articles were evaluated based on the following inclusion criteria: 
focus on laparoscopic sleeve gastrectomy or roux-en-y gastric bypass and bone health, 
written in English, full-length article, studied participants for one-to-two years, and 
included statistical measurements. 
 
Results 
Of the 156 studies that were initially screened, 16 full-length articles were included in the 
final analysis. The articles described a lower loss of bone density at the lumbar spine, 
femoral neck, forearm, and total hip after laparoscopic sleeve gastrectomy when compared 
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to roux-en-y gastric bypass, however, these studies lack statistical power due to the small 
sample sizes of less than 10 participants. 
 
Conclusion 
The number of bariatric surgeries continues to increase worldwide, however, the literature 
provides limited studies that evaluate the effects of bariatric surgery on bone health, more 
than two-years postoperative. Further study is necessary to determine the mechanisms of 
bone loss after bariatric surgery, with great attention to differences in bone health between 
sexes. 
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INTRODUCTION 
 
Obesity is a worldwide public health crisis. The global epidemic of obesity (body mass 
index [BMI], defined as a weight in kilograms divided by the square of height in meters 
[kg/m2], ≥ 30) affects more than 650 million adults, aged 18 years and older (World Health 
Organization, 2017). Recent estimates reveal that obesity impacts more than one-third of 
the United States (US) adult population (Ogden et al., 2015).The excessive accumulation 
of body fat increases the risk of morbidity (e.g. hypertension, coronary heart disease, 
disability, stroke, type 2 diabetes mellitus (T2DM), and certain cancers) and mortality 
(World Health Organization, 2017; National Heart, Lung, and Blood Institute, 2000; Jensen 
et al., 2013; Hruby and Hu, 2015; National Institutes of Health, 1998; Bhaskaran et al., 
2014). The onset of obesity-related comorbidities increases with increasing BMI in the 
different subcategories: grade I obesity (BMI of 30 kg/m2 to 34.9 kg/m2), grade II obesity 
(BMI 35 kg/m2 to 39.9 kg/m2), and morbid obesity (BMI ≥ 40 kg/m2).  Grade I and II 
obesity rates have plateaued within recent years, however, the subcategory of morbid 
obesity in adults continues to rise in the US, with an estimate of 6.4% of the US population 
being morbidly obese (Ogden et al., 2014).  Obesity is a multifactorial disease that severely 
impacts the regulation and stimulation of organ processes, leading to health complications 
and a lower quality of life.  
Treatment modalities of obesity are many-fold, with the first line of treatment being 
lifestyle modification (caloric restriction, increase physical activity, and behavioral 
therapy). However, lifestyle modifications are often ineffective in the long-term (Golden, 
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2017; Wadden et al., 2012). An alternative treatment for obesity is pharmacotherapy. 
Pharmacotherapy utilizes drugs to improve or prevent complications of metabolic diseases 
and promote weight loss. The United States Food and Drug Administration (FDA) has 
approved short-term (e.g. benzphetamine and phentermine) and long-term (e.g. lorcaserin, 
orlistat, and the combination of phentermine and topiramate) drugs to combat obesity (Joo 
and Lee, 2014). However, monotherapies require high doses that cause severe side effects 
or are moderately efficacious (Joo and Lee, 2014; Wilding, 2017; Colon-Gonzalez et al., 
2013). A combination of short and long-term pharmacotherapies and lifestyle modification 
can improve weight loss and health status in obese adults; unfortunately, the long-term 
effects of these drugs are uncertain (Joo and Lee, 2014). Similarly, therapeutic diets, with 
and without support groups, lack long-term sustainability in treating obesity (Buchwald et 
al., 2004).  
In 1991, the National Institutes of Health established medical guidelines for the 
long-term treatment of obesity, surgical therapy, known as bariatric surgery. Currently, 
these guidelines are utilized to identify adults that medically qualify for this surgical 
treatment modality. These guidelines include BMI ≥ 40 kg/m2 (e.g. morbidly obese) or 
BMI ≥ 35 kg/m2 with the presence of a comorbidity such as sleep apnea or T2DM 
(Buchwald et al., 2004). Worldwide bariatric surgeries have increased in popularity. In 
2015 there were 196,000 procedures performed in the US alone. Of these, 53.8% were 
laparoscopic sleeve gastrectomy (LSG) and 23.1% were roux-en-y gastric bypass (RYGB) 
(American Society of Bariatric Surgery, 2016). This has been a dramatic change since 
2011, there were 158,000 bariatric procedures performed with the top two being RYGB at 
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36.7% and the adjustable gastric band at 35.4% (American Society of Bariatric Surgery, 
2016). Presently, LSG is the most performed bariatric surgery in the US, Canada, and 
Asia/Pacific regions (Angrisani et al., 2015).  
Bariatric surgeries are classified into three main categories: malabsorptive, 
restrictive, or combination. A malabsorptive procedure limits food absorption in the 
intestinal track by bypassing a portion of the small intestine (Allen et al., 2013). A 
restrictive procedure limits food intake by reducing the size of the stomach and a 
combination procedure is both malabsorptive and restrictive (Allen et al., 2013). 
Malabsorptive or surgical resection techniques prove to be more effective compared to 
restrictive techniques (Owen et al., 2017). Bariatric surgery is an effective weight loss tool 
for obesity and results in the reduction or remission of obesity-linked comorbidities, such 
as T2DM, hyperlipidemia, hypertension, and obstructive sleep apnea (Buchwald et al., 
2004; Svane and Madsbad, 2014). Bariatric surgery is a means of delivering sustained 
weight loss, with over 50% excess weight loss achieved after surgical intervention and 
sustained for prolonged periods (Bennet et al., 2007).  
Bariatric surgery is an effective treatment modality for weight loss and the 
remission or reduction of obesity-related comorbidities (Buchwald et al., 2004); however, 
the effects of this surgical treatment may have a negative effect on bone homeostasis 
(Carlin et al., 2009, Casagrande et al., 2009; Yu et al., 2013; Azim and Kashyap, 2016). 
The gradual increase in the morbidly obese subpopulation and the likelihood that this 
population will undergo bariatric surgery, it is imperative that future research examines the 
negative effects on bone metabolism after bariatric surgery. The aim of this review is to 
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summarize skeletal changes in clinical studies of bariatric procedures, including a 
discussion of osteoporosis in obese participants undergoing substantial weight loss through 
bariatric procedures.  
For this review, PubMed articles were reviewed through November 1 2017, using 
the following search terms: ‘bariatric surgery’, ‘laparoscopic sleeve gastrectomy’, ‘gastric 
sleeve’, ‘vertical sleeve gastrectomy’, ‘gastric bypass’, ‘roux-en-y gastric bypass’, ‘dual-
energy X-ray absorptiometry’, ‘fracture’, ‘osteoporosis’, ‘bone’, ‘osteopenia’, 
‘gastrointestinal hormones’, ‘amylin’, ‘peptide tyrosine tyrosine’, ‘ghrelin’, ‘insulin’, 
‘glucagon-like peptide 1’,  and ‘glucose-dependent insulinotropic polypeptide’. References 
from retrieved articles were also used. 
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TYPE 2 DIABETES MELLITUS AND OBESITY 
 Diabetes is a chronic disease that affect more than 30 million in the US. A troublesome 
increase in the incidence of diabetes among children has recently been reported (World 
Health Organization, 2017). Diabetes occurs when the blood glucose is elevated for a 
prolonged period of time and cells throughout the body (e.g. myocytes, hepatocytes, and 
adipocytes) do not respond properly to insulin (a state known as insulin resistance; Centers 
of Disease Control and Prevention, 2017).  The lack of a proper response from these cells 
leads to an accumulation of glucose in the blood that cannot be utilized by cells for energy, 
causing the development of type 2 diabetes mellitus (T2DM).  
T2DM is a metabolic disease that occurs when the body does not use insulin 
efficiently (National Institute of Diabetes and Digestive and Kidney Diseases, 2009). A 
higher BMI is an established risk factor for T2DM, with a prevalence of 11% in adults aged 
20 years and older and with a projected 10% increase by 2050 (Eckel et al., 2011). In 
women, there is a five-fold increase in the development of diabetes with a BMI greater 
than 25 kg/m2, 28-fold with BMI greater than 30 kg/m2, and nearly a 90-fold increase with 
a BMI greater than 35 kg/m2 (Azim and Kashyap, 2016). The increase in the risk of diabetes 
with an increase in BMI is also seen in men. Men are 6.7 times more likely to develop 
diabetes if their BMI is greater than 25 kg/m2 (Azamin and Kashyap, 2016).   
Studies have identified links between obesity and T2DM involving 
proinflammatory cytokines (tumor necrosis factor and interleukin-6), insulin resistance, 
unbalanced fatty acid metabolism, and cellular processes such as mitochondrial 
dysfunction and endoplasmic reticulum stress (Leite et al., 2017; Ye et al., 2013).  In obese 
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adults, the relative risk of T2DM is not solely determined by the amount of adipose tissue, 
but where it accumulates.  An increase in visceral adiposity (fat around the internal organs), 
subcutaneous fat (accumulation of fat under the skin), increased abdominal girth or waist-
to-hip ratio, is associated with the metabolic syndrome, T2DM, and cardiovascular disease 
(CVD) (Eckel et al., 2011; Yarutu, 2011).  
Visceral adiposity is more strongly associated with the development of adverse 
cardio metabolic factor rather than subcutaneous fat. Eckel et al. suggests that different 
subtypes of adipose tissue (e.g. white versus brown fat) may affect glucose homeostasis 
differently due to functional differentiation (2011). In prospective studies, over a course of 
10 years there was a 49% increase in the incidence of diabetes in non-diabetic overweight 
adults for every kilogram gained in a year (Yarutu, 2011). Current research demonstrates 
that the impact of obesity on T2DM is multifactorial and there are numerous contributing 
factors whose mechanisms are uncertain and weight loss has been shown to aid in the 
decrease of T2DM. 
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TYPES OF BARIATRIC SURGERIES 
 
The aim of bariatric procedures is to limit food intake and/or the absorption of nutrients in 
the intestines (Allen et al., 2013), to achieve considerable weight loss and the remission of 
comorbidities. The various surgical procedures differ based on the mechanism of 
gastrointestinal restriction category: malabsorptive, restrictive, or combination. The four 
bariatric procedures that are commonly performed in the US include: laparoscopic 
adjustable gastric band, laparoscopic sleeve gastrectomy, biliopancreatic bypass with 
duodenal switch, and the roux-en-y gastric bypass; each of these procedures are explained 
below, however, this review will focus on the roux-en-y gastric bypass and the laparoscopic 
sleeve gastrectomy because these bariatric procedures account for the most performed 
procedures worldwide.   
 
Laparoscopic Adjustable Gastric Band  
The laparoscopic adjustable gastric band is a restrictive procedure in which a silicone band 
connects to a self-sealing reservoir that is implanted beneath the skin. As shown in Figure 
1, a band is placed around the top portion of the stomach to create a smaller gastric pouch, 
which allows for adjustments of the stroma diameter to increase or decrease the rate of 
food passage from the gastric pouch to the stomach (Bennet et al., 2007). Distension of the 
gastric pouch leads to reduced caloric intake due to early meal termination because it causes 
an early sensation of satiety. On average, 50% of excess weight is lost by patients and the 
main obesity comorbidities (e.g. hypertension, diabetes, respiratory disease, and 
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osteoarthritis) improve markedly (Bennet et al., 2007). The complications that can arise 
with this procedure include band slippage, band erosion, esophageal dilation, and portacath 
migration; with slippage, there can be partial or total gastric obstruction that often requires 
surgical correction (Dargent, 2005).  
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Figure 1. Laparoscopic Adjustable Gastric Band 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: Neff, KJ, et al. “Bariatric Surgery: the Challenges with Candidate Selection, Individualizing 
Treatment and Clinical Outcomes.” BMC Medicine, BioMed Central, 10 Jan. 2013, 
bmcmedicine.biomedcentral.com/articles/10.1186/1741-7015-11-8. 
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Laparoscopic Sleeve Gastrectomy  
In the laparoscopic sleeve gastrectomy (LSG), a restrictive procedure, nearly 80% of the 
outer margin of the stomach is removed to restrict food intake, as shown in Figure 2; which 
leads to feeling less hungry, satisfied sooner, and the loss up to 75% of excess body weight 
(Bennett et al., 2007). The outer margin of the stomach that is removed, contains the 
hormone ghrelin, which triggers an individual to be hungry. The reduced stomach 
resembles the shape and size of a banana, connecting the esophagus to the small intestine 
leaving the pylorus (muscle that controls emptying food from the stomach into the 
intestine) intact making the patient feel fuller sooner and resulting in long-term weight loss. 
Complications that can arise with LSG, a non-reversible procedure, include the potential 
for patients to develop long-term vitamin deficiencies, lack of sustainability of weight loss, 
and earlier complication rate than the LAGB (Sarkhosh et al., 2013).  
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Figure 2. Laparoscopic Sleeve Gastrectomy 
 
 
Source: Neff, KJ, et al. “Bariatric Surgery: the Challenges with Candidate Selection, Individualizing 
Treatment and Clinical Outcomes.” BMC Medicine, BioMed Central, 10 Jan. 2013, 
bmcmedicine.biomedcentral.com/articles/10.1186/1741-7015-11-8. 
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Biliopancreatic Bypass with Duodenal Switch  
The biliopancreatic bypass with duodenal switch is a malabsorptive procedure that is ideal 
for morbidly obese individuals that have a BMI greater than 60 kg/m2, as this procedure is 
highly effective for severe weight loss. The outer portion of the stomach is removed and 
the mid-section of the small intestine is attached to the last segment of the duodenum; this 
is known as the duodenal switch. As shown in Figure 3, the separated section of the 
intestine is not removed, it is reattached to the end of the intestine. This allows for the 
pancreatic digestive fluid to flow into part of the intestine and assist with food digestion. 
The reconnection of the intestine is known as the biliopancreatic diversion. Therefore, food 
that is consumed will bypass most of the small intestine, limiting the amount of caloric and 
nutrition absorption. The smaller size of the stomach and the lack of full caloric absorption 
(malabsorption) aids weight loss. The side effects of this procedure can be inadequate 
digestion, increased frequency of stomach ulcers, and the dumping syndrome, which is 
when food moves quickly from the stomach to the duodenum causing symptoms such as 
sweating, shaking, and nausea (National Institute of Diabetes and Digestive and Kidney 
Diseases, 2013).  
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Figure 3.  Biliopancreatic Bypass with Duodenal Switch  
 
 
Source: Neff, KJ, et al. “Bariatric Surgery: the Challenges with Candidate Selection, Individualizing 
Treatment and Clinical Outcomes.” BMC Medicine, BioMed Central, 10 Jan. 2013, 
bmcmedicine.biomedcentral.com/articles/10.1186/1741-7015-11-8. 
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Roux-en-Y Gastric Bypass  
The roux-en-Y gastric bypass (RYGB) is two-fold weight loss bariatric procedure that is 
restrictive and malabsorptive. It limits the amount of food consumed before feeling full 
and prevents the body from absorbing a significant amount of calories. A small pouch, size 
of a golf ball that can hold around 28 grams of food, is inserted at the end of the esophagus 
(this can be seen in Figure 4). The remainder of the stomach is attached to the top left 
portion of the small intestines. The small intestine that is still connected with the remainder 
of the stomach is then attached to the bottom of the small intestine, at the roux limb. 
Connecting the small intestine to the remainder of the stomach allows for digestive 
secretions of the stomach to meet with the food in the small intestines.  
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Figure 4. Roux-en-Y Gastric Bypass   
 
 
Source: Neff, KJ, et al. “Bariatric Surgery: the Challenges with Candidate Selection, Individualizing 
Treatment and Clinical Outcomes.” BMC Medicine, BioMed Central, 10 Jan. 2013, 
bmcmedicine.biomedcentral.com/articles/10.1186/1741-7015-11-8. 
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OSTEOPOROSIS 
The weakening of structural bone tissue and the loss of bone mineral density, leads to 
fragility of the bone, resulting in an increased risk of hip, wrist, and spine fractures 
(National Institutes of Health, 2012). This condition is known as osteoporosis. As shown 
in Figure 3A, healthy bones are porous—have holes and spaces—however, in osteoporosis 
the holes and spaces of the bone are much larger than in the healthy bone (Figure 3B). 
These wider holes and spaces of the bone make the bone less dense and alter the structural 
integrity of the tissue and more likely to break.  In the United States, more than 53 million 
individuals are either at high risk of developing osteoporosis due to low bone mass or 
already have osteoporosis (National Institutes of Health, 2016). Some of the risk factors 
for osteoporosis include: (1) family history of osteoporosis, (2) thin or small body frame, 
(3) lack of calcium, and (4) postmenopausal women or having an early menopause. 
 
Figure 5. Images of healthy porous bone and osteoporotic bone.  
 
Source: Spinasanta, Susan. “Osteoporosis and Spinal Fracture Management Tool: Own the 
Bone®.” SpineUniverse, www.spineuniverse.com/professional/news/nass/osteoporosis-spinal-fracture-
management-tool-own-bone. 
B. 
A. 
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The human skeleton continuously undergoes repair and maintenance.  The production of 
bone is known as bone modeling. Bone modeling produces bone without prior bone 
resorption. The reconstruction of bone following bone resorption is known as bone 
remodeling. The process of bone remodeling is when bone resorption targets particular 
sites of the bone that need repair and this repair is followed by bone formation at the same 
site of repair. It is important to note that bone remodeling rates increases with age (Recker 
et al., 2004).  The balance of bone modeling and remodeling is needed to maintain bone 
homeostasis. When bone remodeling occurs more than bone modeling, bones become 
fragile and are easier to fracture.  
The three major bone cell types that are involved in bone remodeling are 
osteoclasts, osteoblasts, and osteocytes. The function of osteoclasts is two-fold: to reabsorb 
bone mineral and organic matrix of the bone and to signal to osteoblasts to initiate bone 
formation (Raisz, 1999; Matsuo et al., 2008). The function of osteoblasts is the deposition 
of bone matrix proteins prior to mineralization; in addition, when osteoblasts are trapped 
in the matrix they become osteocytes (2003). Additional cells will undergo apoptosis or 
form new, flattened osteoblasts to line the surface of the bone, and signal regulation of 
differentiation and activity of osteoclasts (Mackie, 2003). Lastly, osteocytes function in the 
sensing of mechanical stimuli and orchestrate bone remodeling, hence maintaining mineral 
homeostasis (Bonewald, 2008; Raggatt et al., 2010) and bone strength (Felsenberg et al., 
2005; Davison et al., 2006). 
Bone mass and strength are increased by mechanical loading, which stimulates the 
formation of new bone in areas that experience high strain (Robling et al., 2007). 
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Mechanical loading reduces sclerostin gene expression. Sclerostin is a small protein that 
inhibits osteoblastic bone formation through the wnt/β-catenin pathway (Lewiecki, 2014; 
Robling et al., 2007; Bonewald and Johnson, 2008). Osteoporosis is a preventable disease; 
however, the disease is often silent as symptoms can go undetected for many years and the 
disease will only be diagnosed many time only after a fracture has occurred. 
 
Relationship of Sex and Osteoporosis 
The National Osteoporosis Foundation estimates that one in two women and up to one in 
four men, aged 50 years or older will break a bone due to osteoporosis (2017). The 
prevalence and rate of fractures due to osteoporosis are higher among postmenopausal 
women than in older men, a fact that contributed to label osteoporosis a women’s disease 
(Cawthon, 2011). However, osteoporosis and the complications that arise with this disease 
affects both sexes, at different ages and rates (Alswat, 2017). The differences in bone 
geometry, bone size, and bone strength between men and women contribute to the 
differences in fracture risk.  
 Estrogen plays an important role in the maturation, growth, and regulation of bone 
turnover in women (Vaananen and Harkonen, 1996). Studies have indicated that the main 
function of estrogen is to prevent bone loss by inhibiting osteoclasts bone resorption, 
however, the mechanisms are uncertain (Takashi et al., 1997).  Estrogen deficiency occurs 
during menopause and induces cancellous and cortical bone loss; increased bone resorption 
in cancellous bone leads to the destruction of local bone architecture and general bone loss 
(Vaananen and Harkonen, 1996). Postmenopausal women are severely impacted by 
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osteoporosis due to the lack of estrogen, however, men are more likely to have 
osteoporosis-related complications and have a higher mortality rate of fractures (Alswat, 
2017). 
 
Relationship of Type 2 Diabetes Mellitus and Osteoporosis 
Prior studies suggested that excess body weight can reduce the risk of developing 
osteoporosis and those with excess body weight were more likely to be protected against 
osteoporosis (Vranken, 2017;U.S. Department of Health and Human Services, 2004; 
National Institute of Health, 2016); however, excess body weight is common among those 
that have T2DM (National Institute of Health, 2016). In people with T2DM there is a 
decrease in bone density and an increase fractures, this may be due to increased falls 
because of vision and nervous damage. Moreover, T2DM increases fractures due sedentary 
lifestyle that negatively impacts bone quality and structure (National Institute of Health, 
2016).    
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BONE MINERAL DENSITY 
The bone mineral density (BMD) is the measure of bone density (strength of the bones), 
which is mainly dependent on calcium content. A BMD test is utilized to diagnose 
osteoporosis prior to fracture or broken bones therefore this test is useful to estimate the 
risk of fracture and the current state of the bone (National Osteoporosis Foundation, 2017). 
From a BMD test a t-score is given, which is calculated by subtracting the mean BMD of 
a young-adult reference population from the patients BMD and dividing by the standard 
deviation of the reference population. As shown in Table 1, a score of 0 indicates that the 
BMD is equal to the normal range of a healthy adult, scores of +1 standard deviation (SD) 
and -1SD are considered normal, a score of -1SD and -2.5SD indicates low bone mass and 
risk of osteoporosis, and a score of -2.5SD or lower indicates osteoporosis. A score that is 
lower than -2.5SD would indicate severe osteoporosis (National Institute of Health, 2015). 
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Table 1. T-scores of Bone Mineral Density 
  
 
 
 
 
 
 
 
 
 
 
Source: Adapted from “Bone Mass Measurement: What the Numbers Mean.” National Institutes 
of Health, U.S. Department of Health and Human Services, June 2015, www.bones.nih.gov/health-
info/bone/bone-health/bone-mass-measurement-what-numbers-mean 
 
 
 
 
 
 
 
 
 
 
 
Bone density is within 1 SD (+1 or −1) of the young adult mean. 
Bone density is between 1 and 2.5 SD below the young adult 
mean (−1 to −2.5 SD). 
Bone density is 2.5 SD or more below the young adult mean 
(−2.5 SD or lower). 
Bone density is more than 2.5 SD below the young adult mean, 
and there have been one or more osteoporotic fractures. 
Normal 
Low Bone Mass 
Osteoporosis 
Severe Osteoporosis 
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IMPACT OF BARIATRIC SURGERY ON BONE HEALTH 
RYGB and Bone Health 
Until 2012, RYGB was the leading bariatric procedure worldwide. An average weight loss 
of 43 kg and reduction of 17kg/m2 in BMI, can be achieved on average postoperatively 
with RYGB (Yu, 2014). In relation to RYGB, bone pain, hypocalcemia, osteomalacia and 
osteitis fibrosis, height loss, and an elevation in serum markers of bone turnover have been 
identified (Yu, 2014). Changes in urinary and serum makers of bone density were identified 
as early as three months postoperative and have persisted throughout the second 
postoperative year (Yu, 2014).  
 As shown in Table 2, a drastic decline in bone density following RYGB was 
described by studies that used dual-energy x-ray absorptiometry (DXA) to measure bone 
mineral density. The study conducted by von Mach et al., indicated bone density changes 
over a two-year period in four women (2004). In two years, these four women had a severe 
decline in vertebral BMD of -12% and total BMD of -3.5%.  In 2008, Fleischer et al. 
examined the effects of RYGB on bone density and found a significant decrease in the 
femoral neck (-9.2%) and total hip (-8%) among 18 women and 5 men.  
Vilarrasa et al., described bone density changes over a three-year follow-up study 
in 62 women undergoing RYGB, a fourth of whom were postmenopausal (2011). Within 
the first postoperative year, women experienced bone loss at the femoral neck of -10% and 
at the lumbar spine of -3%, with no changes in 25D and parathyroid hormone levels. 
Additional decline in the lumbar spine (-3.1%) and femoral neck (-2.7%) occurred between 
years one and three, despite weight regain.  
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 Casagrande et al., described bone density changes in 22 women post RYGB within 
the first postoperative year (2012). There was a significant decline of -7.3% in the lumbar 
spine, total hip of -8.6%, and the femoral neck of -8.8%. Similarly, the results described 
by Stein et al., indicated that among 14 women within one year postoperative RYGB there 
was a significant decline in bone density of the femoral neck (-7.9%) and total hip (-8.1%).  
 In Table 2, numerous studies using DXA have reported changes in BMD, although 
spine BMD measured by DXA declines at a slower than total hip BMD in the first year 
postoperative RYGB (Fleischer et al, 2008; Carlin 2009; Carrasco et al., 2009; Nogues et 
al., 2010; Vilarrasa et al., 2011; Casagrande et al., 2012; Yu, 2013; Stein et al., 2013). 
Some studies have indicated a decline of 3 to 7% in the lumbar spine within the first year 
(von Mach et al., 2004; Carrasco et al., 2009; Nogues et al., 2010; Vilarrasa et al., 2011; 
Casagrande et al., 2012; Yu et al, 2013), however, this was not seen in other studies 
(Fleischer et al., 2008; Carlin et al. 2009; Stein et al., 2013) Similarly, a -25% decline in 
whole body BMD at one year postoperative RYGB was seen in some studies (von Mach 
et al., 2004;Mahdy et al., 2008;  Carrasco et al., 2009; Vilarrasa et al., 2011) but not all 
(Carlin et al., 2009; Yu et al., 2013). In the majority of these studies, the increase in bone 
resorption markers exceeded the increase in bone formation suggesting an unbalanced bone 
homeostasis in individuals undergoing RYGB, which is consistent with net bone loss. 
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Table 2. Study characteristics  
   Region Measured BMD (g/cm2) 
        
Study Surgery Type N   Baseline 12 months 24 months % Change 
        
Von mach 2004 RNYGB 4 Total BMD 1.26 ± 0.04   -3.5 ± 1.0 
   Vertebral BMD 1.15 ± 0.04   -12.8 ± 3.0 
        
        
Pereira 2007 RNYGB 8 Forearm  0.708 ± 0.01 0.678 ± 0.01 −  
   Femoral neck 0.961 ± 0.04 0.849 ± 0.03  −  
   Lumbar spine  1.135 ± 0.04  1.018 ±  0.02  −  
        
Fleischer 2008 RNYGB 23 Femoral neck − − − -9.20% 
   Total hip   − − − -8.00% 
   Lumbar spine  − − − 1.80% 
  23 Forearm  − − − 0.30% 
        
Mahdy 2008 RNYGB 70 Total BMD 1.26 ± 0.03  1.22  ± 0.015 − -4.0% 
        
Carrasco 2009 RNYGB 42 Total BMD 1.23 ± 0.53 1.19 ± 0.63 − -4.0% 
   Lumbar spine 1.49 ± 0.11 1.38 ± 0.14 − -11% 
   Total hip 1.28 ± 0.09 1.14 ± 0.09 − -14% 
        
Carlin 2009 RNGB 30 Total BMD − − − -1.0% 
   Spine − − − -1.0% 
   Hip − − − -8.0% 
   Forearm − − − -1.0% 
        
Nogues 2010 LSG 8 Lumbar spine 1.013 ± 0.13 0.967 ± 0.13 − -5.0% 
   Total hip   1.009 ± 0.07 0.936 ± 0.07 − -7.0% 
   Forearm 0.661 ± 0.60 0.656 ± 0.05 − -0.05% 
        
 RNYGB 7 Lumbar spine 1.1 ± 0.1 1.026 ± 0.07 − -7.0% 
   Total hip   1.054 ± 0.07 0.929 ± 0.05 − -0.50% 
        
Vilarrasa 2011 RNYGB 62 Femoral neck 1.1 ±  0.11 0.98 ±  0.11 −  
   Lumbar spine 1.1 ±  0.12 1.06 ±  0.13 −  
        
Legro 2012 RNYGB 29 Total BMD 1.19 ± 0.08 1.19 − 0 
        
Casagrande 2012 RNYGB 22 Lumbar spine 1.13 ± 0.11 1.04 ± 0.09 − -7.3% 
   Total hip 1.03 ± 0.15 0.94 ± 0.16 − -8.6% 
        
Yu 2013  30 Spine aBMD 1.158 ± 0.174   -3.3 ± 0.08% 
   
Total hip 
aBMD 1.087 ± 0.150   -8.9 ± 0.08% 
   
Femoral neck 
aBMD 0.964 ± 0.164   -6.1 ± 1.2%  
   
One-third 
radius aBMD 0.707 ± 0.59   − 
        
        
Stein 2013 RNYGB 14 Total hip   − − − -5.20% 
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Table 2. Study characteristics, continued 
 
        
   Region Measured BMD (g/cm2) 
    
Study 
Surgery 
Type N   Baseline 12 months 24 months % Change 
Ruiz-Tovar 2013 LSG 42 Total BMD 1.18 ±  0.09 1.24 ±  0.08 − -6.0% 
        
 RNYGB 30 Total BMD     
        
Maghrabi 2015 RNYGB 20 Total hip   1.1 (1.0, 1.3) 
-6.6 (-9.3, -
3.8) -9.5 (-13.2, -6.7) − 
   Lumbar spine 1.3 (1.1, 1.5) 
-0.1(-2.1, 
3.4) 0.4 (-1.9, 2.2) − 
 LSG 20 Total hip   1.1 (1.1, 1.2) 
-7.6 (-8.5, -
5.7) -9.2 (-12, -5.4) − 
   Lumbar spine 1.2 (1.1, 1.3) 
-0.7 (-3.1, 
1.9) -2.3 (-4.8, 1.6) − 
        
Yu 2015 RNYGB 30 Total hip   0% 7.40% 10%  
   Lumbar spine 0% 3.80% 6%  
        
Bredella 2017 RNYGB 11 Spine aBMD 1.13 ± 0.11 − − − 
   Spine T-score 0.7 ± 1.0 0.3 ± 1.2 − − 
        
   Total hip aBMD  1.11 ± 0.15 − − − 
   Total hip T-score 1.1 ± 0.8 0.1 ± 0.7 − − 
        
   
Femoral neck 
aBMD  0.94 ± 0.16 − − − 
     
Femoral neck T-
score  0.5 ± 1.0 −0.6 ± 0.6 − − 
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LSG and Bone Health 
The LSG is a relatively new bariatric surgery that has increased in popularity since 2008, 
as indicated by a four-fold increase in surgical procedures between 2008 and 2011. 
Currently, LSG is the leading bariatric surgery worldwide, however, there are only few 
studies that have examined the effect of LSG on bone health. Nogues et al., found a 
significant decline in bone density among 8 women one year postoperative LSG, with a 
net loss of -4.6% at the lumbar spine, -7.1% of the total hip, and -8.3% of the femoral neck 
(2010). In contrast, Ruiz-Tovar et al., found that a 5.7% in the spine at one year 
postoperative and 7.9% at year two postoperative (2013). The discrepancies between the 
results of LSG on the lumbar spine are uncertain, and this could be a result of reduction of 
vitamin D deficiency; whereas other studies indicated that postoperatively, vitamin D 
deficiency either stable or worsened.   
 
Comparison between RYGB and LSG on Bone Health 
Nogues et al., compared bone density postoperatively between RYGB and LSG, finding 
that the loss of bone density at the lumbar spine, total hip, femoral neck, and forearm was 
less after LSG when compared to RYGB (2010). However, the analysis lacks power 
because the sample sizes RYGB (7) and LSG (8) and therefore could not conclude that 
there were statistically differences between the two groups. In contrast, Vilarrasa et al., 
described that changes in bone density of the femoral neck and lumbar spine were similar 
between RYGB and LSG, but preoperative DXA scans were not collected and therefore 
the difference between pre-and post-operative changes in bone loss could not be evaluated 
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(2013).  Further investigation is needed to understand the impact of RYGB and LSG on 
bone loss.    
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POSSIBLE MECHANISMS 
 
Alternations in the anatomy of the stomach is associated with modifications in the 
secretions of gastrointestinal hormones, especially in procedures that reroute the small 
intestine connections (e.g. RYGB).   
 
Ghrelin 
Ghrelin, a gut hormone, described in 1999 as an endogenous ligand for the growth hormone 
secretagogue receptor (GSH-R), a G-coupled receptor. Secreted by endocrine cells of the 
oxyntic—acid secreting—glands of the gastric fundus, ghrelin binds to GSH-R and 
promotes appetite regulation, release of growth hormone, and energy conservation (Makris 
et al., 2017; Zingman et al., 2016). Ghrelin is broadly expressed in the central nervous 
system and in peripheral tissues (e.g. cardiac cells and immune cells) (Aparecida da Silva 
Pereira, 2017). The levels are increased before meals and suppressed after meals. Obesity-
related conditions, reduce ghrelin levels and initiate chronic low-grade inflammation 
(Aparecida da Silva Pereira, 2017). Obesity impacts ghrelin by causing it to directly act on 
the hypothalamic neurons that are responsible for feeding behavior to regulate the appetite. 
In addition, ghrelin is known to regulate bone cell formation and metabolism (Pradhan et 
al., 2013) therefore reducing ghrelin levels may have a negative impact on bone 
metabolism post bariatric procedure.  
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Insulin 
The pancreas is an organ that is located behind the stomach in the upper left abdomen. It 
has two main functions: aid in digestion (exocrine) and the regulation of blood glucose 
(endocrine). The endocrine function occurs by the actions of the hormones insulin and 
glucagon. In the pancreas, there are clusters of cells—islets of Langerhans—that contain 
beta (β) cells that secrete and release insulin into the bloodstream. Insulin has a critical role 
in the utilization of digested foods for energy. After food consumption, the digestive tract 
breaks down carbohydrates into starches and glucose; the rise blood glucose levels 
stimulate the pancreas to release insulin. The insulin released from the pancreas enters the 
bloodstream and travels to cells throughout the body, to induce glucose absorption in 
various tissues and organs. In addition, liver cells (hepatocytes) and muscle cells 
(myocytes) absorb and store excess glucose—stored excess glucose is called glycogen—
from the bloodstream, thereby lowering circulating glucose levels.  
An inadequate response to insulin, typical of diabetic condition, in myocytes, 
hepatocytes, and adipocytes causes an insufficient absorption of excess glucose from the 
bloodstream. Glucose accumulation in the bloodstream signals the pancreatic β cells to 
release insulin which is however no longer able to lower blood glucose. This is known as 
insulin resistance. When the pancreatic β cells can no longer maintain the high level of 
insulin production, excess glucose will continue to accumulate in the bloodstream, leading 
to prediabetes and TD2M. Insulin resistance mechanisms are not fully understood; 
however, current research showed that excess weight and physical inactivity are two major 
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contributors. Moreover, the accumulation of fat around the waist produces hormones that 
can cause insulin resistance, hypertension, and CVD.  
Excess abdominal fat contributes to the development of chronic inflammation, 
which can also cause the development of insulin resistance, T2DM, and CVD. Myocytes 
use more glucose than other tissues and active muscles burn glucagon for energy and 
reabsorb glucose from the bloodstream, keeping the blood glucose levels balanced. Studies 
indicate that muscles are more sensitive to insulin after exercise—they will consume more 
glucose—lowering the blood glucose levels and reversing insulin resistance. Losing weight 
and gaining muscle can reduce insulin resistance and prevent or delay the onset of T2DM.  
 
Insulin and Bone Metabolism 
Insulin promotes the proliferation of osteoblasts through the mitogen-activated protein 
kinases, phosphatidylinositol-3 kinase, and insulin-like growth factor-1 pathways (Guo, 
2014). Insulin decreases osteoprotegerin level, which stimulates bone resorption and is 
positively associated with bone mineral density (Ferron et al., 2010). Interestingly, Dirksen 
et al. indicated a decrease in insulin levels after RYGB (2012). Therefore, decreases insulin 
levels after RYGB could have a negative impact on bone metabolism and may increase the 
risk of fracture, osteoporosis and other bone-related diseases. However, further 
investigation is needed to test this hypothesis.  
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Glucose-Dependent Insulinotropic Polypeptide 
Glucose-dependent insulinotropic polypeptide (GIP) is secreted by the proximal small 
intestine K cells. This hormone promotes the release of insulin from beta cells (Christensen 
et al., 2011; Parker et al., 2008) and plays a role in fat metabolism (Parker et al., 2008). 
Nearly 50% of the normal release of insulin following food ingestion is due to GIP and 
glucagon-like polypeptide 1.   
  
Glucagon-like Peptide-1  
 Glucagon-like peptide-1 (GLP-1) is secreted by the L cells of the distal ileum and colon 
(Lutz, 2016) and it contributes to sensitize β-cells to glucose concentrations.  Indeed, the 
presence of GLP-1 (as low as 10nM) reduces the concentration of glucose required for 
half-maximal insulin secretion (Doyle and Egan, 2008). GLP-1 levels are increased 
following the RYGB (Dirksen et al., 2012) therefore this increase may be positively affect 
bone metabolism in morbidly obese individuals undergoing gastric surgery; however, 
further studies are needed to clarify this hypothesis.  
 
Amylin 
Amylin is co-secreted with insulin from the beta cells of the pancreas and can be found at 
higher levels in obese patients (Lutz, 2016). A decrease in amylin is expected to have a 
negative impact on bone metabolism, as this peptide hormone decreases bone resportion 
and stimulates bone formations (Shapses and Sukumar, 2012). Studies have described 
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decreased levels of amylin following the RYGB (Bose et al., 2010) but there is a need for 
additional studies to confirm these results.  
 
Peptide Tyrosine Tyrosine   
Peptide Tyrosine Tyrosine (PYY), is secreted by the L cells of the distal ileum and colon, 
and is responsible for reducing appetite (Batterham and Bloom, 2003; Karra et al., 2009). 
Obesity reduces the levels of PYY, while anorexia is associated with increased levels of 
PYY. Increased levels of PYY are also associated with low levels of bone turnover markers 
(Utz et al., 2008). 
 
Vitamin D 
Vitamin D is essential for healthy bones as it assists the body in the absorption of calcium. 
It is made in the skin after exposure to sunlight, however, diet and supplementation can 
also provide vitamin D (Vimaleswaran et al., 2012). After vitamin D is absorbed in the 
body, it is sequestered and stored in tissues (e.g. adipose and muscle) (Soskić et al., 2014). 
In the literature, there is a consistent association between increasing BMI and lower serum 
25-hydroxyvitamin D (25D) concentrations (Soskić et al., 2014). Initial studies indicated 
an association between obesity and high concentrations of parathyroid hormone (PTH), 
low serum 25D concentrations, as well as high 1, 25-dihydroxyvitamin D (1, 25 D) levels 
(Soskić et al., 2014). However, these initial studies had relatively small sample sizes. In 
studies with larger sample sizes, obesity was similarly associated with reduced 25D 
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concentrations, increased PTH concentrations, but decreased 1, 25D concentrations 
(Vanlint, 2013).  
 Bell et al. provided a possible explanation for vitamin deficiency in obese 
individuals that is the lack of sufficient sun exposure and sequestration of vitamin D in 
adipose tissue (1985). In addition, body fat content has been inversely related to serum 25D 
concentration; furthermore the association between 25D and BMI and body weight is even 
stronger than with fat content (McGill et al., 2008). Vimaleswaran et al., suggests a higher 
BMI leads to a lower vitamin D status whereas low vitamin D status had small effects on 
BMI (2012) providing evidence that obesity is a causal factor in the development of 
vitamin D deficiency and not vice versa.  
The mechanisms which lead to low 25D concentrations in obese individuals have 
yet to be fully uncovered. It is possible that sequestration of lipid soluble vitamin D 
metabolites in fat compartments decreases their bioavailability (Soskić et al., 2014). In a 
cross-sectional study, serum levels of vitamin D were inversely associated with BMI after 
adjusting for age, gender, and serum calcium in non-diabetic and diabetic patients; which 
indicates that the status of vitamin D is considered as an important factor in T2DM patients 
(Taheri et al., 2012).  However, Clemente-Postigo et al., found that in prediabetic and 
diabetic individuals that 25D levels were decreased compared to individuals without 
diabetes independent of BMI, but, closely related to indices of glucose metabolism (2015). 
This study suggests that vitamin D deficiency is associated more with the level of 
carbohydrate metabolism than with obesity per se. Further research is needed to establish 
the relationship between vitamin D deficiency and BMI. 
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CONCLUSION 
Treatment modalities for the obesity epidemic have concluded that bariatric surgery is the 
most effective in reducing body weight and obesity-related comorbidities. However, they 
may be long-term effects on bone health and metabolism which warrens further 
investigation. Potentially this could place the subpopulation of the morbidly obese at a 
higher risk of fracture and the development of osteoporosis post operation. Evidence 
suggests variability in the development of negative effects on bone homeostasis, depending 
on the type of bariatric surgery performed. The clinical implications of the development of 
osteoporosis and fracture risk post bariatric surgery are still unclear.  
Future research should include further evaluation of bone mineral density imaging 
modalities to verify the magnitude of bone loss after bariatric surgery. It is essential that 
longitudinal studies evaluate bone loss in bariatric patients more than two years post 
operation, in order to evaluate the long-term impact of surgery on risk of fracture and bone 
metabolism and health.  Understanding the mechanisms of how bariatric surgery 
contributes to bone loss is imperative in understanding the complex interactions between 
bone health, gastrointestinal hormones, adipocytes, and myocytes, leading to potential 
treatments.  
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